Impact of Carbapenem Heteroresistance Among Multidrug-Resistant ESBL/AmpC-Producing Klebsiella pneumoniae Clinical Isolates on Antibiotic Treatment in Experimentally Infected Mice

References

• O’Neill J. Tackling drug-resistant infections globally: final report and recommendations. The Review on Antimicrobial Resistance London, United Kingdom; 2016.
   Google Scholar
• Martelius T, Jalava J, Karki T, et al. Nosocomial bloodstream infections caused by Escherichia coli and Klebsiella pneumoniae resistant to third-generation cephalosporins, Finland, 1999–2013: trends, patient characteristics and mortality. Infect Dis. 2016;48(3):229–234. doi:10.3109/23744235.2015.1109135
   PubMed Web of Science ®Google Scholar
• Gorrie CL, Mirceta M, Wick RR, et al. Gastrointestinal carriage is a major reservoir of Klebsiella pneumoniae infection in intensive care patients. Clin Infect Dis. 2017;65(2):208–215. doi:10.1093/cid/cix27028369261
   PubMed Web of Science ®Google Scholar
• Livermore DM. Beta-lactamases- the threat renews. Curr Protein Pept Sci. 2009;10(5):397–400. doi:10.2174/13892030978935199419538149
   PubMed Web of Science ®Google Scholar
• Bush K, Courvalin P, Dantas G, et al. Tackling antibiotic resistance. Nat Rev Microbiol. 2011;9(12):894–896. doi:10.1038/nrmicro269322048738
   PubMed Web of Science ®Google Scholar
• Girometti N, Lewis RE, Giannella M, et al. Klebsiella pneumoniae bloodstream infection: epidemiology and impact of inappropriate empirical therapy. Medicine. 2014;93(17):298–309. doi:10.1097/MD.000000000000011125398065
   PubMed Web of Science ®Google Scholar
• Karaiskos I, Giamarellou H. Multidrug-resistant and extensively drug-resistant gram-negative pathogens: current and emerging therapeutic approaches. Expert Opin Pharmacother. 2014;15(10):1351–1370. doi:10.1517/14656566.2014.91417224766095
   PubMed Web of Science ®Google Scholar
• Moellering RC Jr. NDM-1 – a cause for worldwide concern. N Engl J Med. 2010;363(25):2377–2379. doi:10.1056/NEJMp101171521158655
   PubMed Web of Science ®Google Scholar
• Nordmann P, Cuzon G, Naas T. The real threat of Klebsiella pneumoniae carbapenemase-producing bacteria. Lancet Infect Dis. 2009;9(4):228–236. doi:10.1016/S1473-3099(09)70054-419324295
   PubMed Web of Science ®Google Scholar
• Grundmann H, Glasner C, Albiger B, et al. Occurrence of carbapenemase-producing Klebsiella pneumoniae and Escherichia coli in the European survey of carbapenemase-producing Enterobacteriaceae (EuSCAPE): a prospective, multinational study. Lancet Infect Dis. 2017;17(2):153–163. doi:10.1016/S1473-3099(16)30257-227866944
   PubMed Web of Science ®Google Scholar
• Tian L, Zhang Z, Sun Z. Antimicrobial resistance trends in bloodstream infections at a large teaching hospital in China: a 20-year surveillance study (1998–2017). Antimicrob Resist Infect Control. 2019;8(1):86. doi:10.1186/s13756-019-0545-z31161033
   PubMed Web of Science ®Google Scholar
• Wong JLC, Romano M, Kerry LE, et al. OmpK36-mediated Carbapenem resistance attenuates ST258 Klebsiella pneumoniae in vivo. Nat Commun. 2019;10(1):3957. doi:10.1038/s41467-019-11756-y31477712
   PubMed Web of Science ®Google Scholar
• Queenan AM, Bush K. Carbapenemases: the versatile beta-lactamases. Clin Microbiol Rev. 2007;20(3):440–458. doi:10.1128/CMR.00001-0717630334
   PubMed Web of Science ®Google Scholar
• Suay-Garcia B, Perez-Gracia MT. Present and future of Carbapenem-resistant Enterobacteriaceae (CRE) infections. Antibiotics. 2019;8(3). doi:10.3390/antibiotics8030122
   Web of Science ®Google Scholar
• Kuper KM, Boles DM, Mohr JF, Wanger A. Antimicrobial susceptibility testing: a primer for clinicians. Pharmacotherapy. 2009;29(11):1326–1343. doi:10.1592/phco.29.11.132619857149
   PubMed Web of Science ®Google Scholar
• Band VI, Weiss DS. Heteroresistance: a cause of unexplained antibiotic treatment failure? PLoS Pathog. 2019;15(6):e1007726. doi:10.1371/journal.ppat.100772631170271
   PubMed Web of Science ®Google Scholar
• Andersson DI, Nicoloff H, Hjort K. Mechanisms and clinical relevance of bacterial heteroresistance. Nat Rev Microbiol. 2019;17(8):479–496. doi:10.1038/s41579-019-0218-131235888
   PubMed Web of Science ®Google Scholar
• Band VI, Satola SW, Burd EM, Farley MM, Jacob JT, Weiss DS. Carbapenem-resistant Klebsiella pneumoniae exhibiting clinically undetected colistin heteroresistance leads to treatment failure in a murine model of infection. mBio. 2018;9(2). doi:10.1128/mBio.02448-17
   Web of Science ®Google Scholar
• Band VI, Crispell EK, Napier BA, et al. Antibiotic failure mediated by a resistant subpopulation in Enterobacter cloacae. Nat Microbiol. 2016;1(6):16053. doi:10.1038/nmicrobiol.2016.5327572838
   PubMed Web of Science ®Google Scholar
• Tan K, Nguyen J, Nguyen K, Huse HK, Nieberg PH, Wong-Beringer A. Prevalence of the carbapenem-heteroresistant phenotype among ESBL-producing Escherichia coli and Klebsiella pneumoniae clinical isolates. J Antimicrob Chemother. 2020;75(6):1506–1512. doi:10.1093/jac/dkaa04832181802
   PubMed Web of Science ®Google Scholar
• Magiorakos AP, Srinivasan A, Carey RB, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect. 2012;18(3):268–281. doi:10.1111/j.1469-0691.2011.03570.x21793988
   PubMed Web of Science ®Google Scholar
• CLSI. Performance Standards for Antimicrobial Susceptibility Testing. 27th ed. CLSI Supplement M100. Wayne, PA: Clinical and Laboratory Standards Institute; 2017
   Google Scholar
• Gude MJ, Seral C, Saenz Y, Gonzalez-Dominguez M, Torres C, Castillo FJ. Evaluation of four phenotypic methods to detect plasmid-mediated AmpC beta-lactamases in clinical isolates. Eur J Clin Microbiol Infect Dis. 2012;31(8):2037–2043. doi:10.1007/s10096-011-1537-y22278294
   PubMed Web of Science ®Google Scholar
• Perez-Perez FJ, Hanson ND. Detection of plasmid-mediated AmpC beta-lactamase genes in clinical isolates by using multiplex PCR. J Clin Microbiol. 2002;40(6):2153–2162. doi:10.1128/JCM.40.6.2153-2162.200212037080
   PubMed Web of Science ®Google Scholar
• Xu H, Huo C, Sun Y, et al. Emergence and molecular characterization of multidrug-resistant Klebsiella pneumoniae isolates harboring bla CTX-M-15 extended-spectrum beta-lactamases causing ventilator-associated pneumonia in China. Infect Drug Resist. 2019;12:33–43. doi:10.2147/IDR.S18949430588046
   PubMed Web of Science ®Google Scholar
• Kim HB, Park CH, Kim CJ, Kim EC, Jacoby GA, Hooper DC. Prevalence of plasmid-mediated quinolone resistance determinants over a 9-year period. Antimicrob Agents Chemother. 2009;53(2):639–645. doi:10.1128/AAC.01051-0819064896
   PubMed Web of Science ®Google Scholar
• Luo Y, Yang J, Zhang Y, Ye L, Wang L, Guo L. Prevalence of beta-lactamases and 16S rRNA methylase genes amongst clinical Klebsiella pneumoniae isolates carrying plasmid-mediated quinolone resistance determinants. Int J Antimicrob Agents. 2011;37(4):352–355.21376540
   PubMed Web of Science ®Google Scholar
• Compain F, Babosan A, Brisse S, et al. Multiplex PCR for detection of seven virulence factors and K1/K2 capsular serotypes of Klebsiella pneumoniae. J Clin Microbiol. 2014;52(12):4377–4380. doi:10.1128/JCM.02316-1425275000
   PubMed Web of Science ®Google Scholar
• Turton JF, Perry C, Elgohari S, Hampton CV. PCR characterization and typing of Klebsiella pneumoniae using capsular type-specific, variable number tandem repeat and virulence gene targets. J Med Microbiol. 2010;59(Pt 5):541–547. doi:10.1099/jmm.0.015198-020110386
   PubMed Web of Science ®Google Scholar
• He J, Jia X, Yang S, et al. Heteroresistance to carbapenems in invasive Pseudomonas aeruginosa infections. Int J Antimicrob Agents. 2018;51(3):413–421. doi:10.1016/j.ijantimicag.2017.10.01429127047
   PubMed Web of Science ®Google Scholar
• U.S. Department of Health and Human Services. Centers for Disease Control and Prevention. Antibiotic Resistance Threats in the United States. Atlanta, GA: Centers for Disease Control and Prevention; 2013.
   Google Scholar
• World Health Organization. WHO Publishes List of Bacteria for Which New Antibiotics are Urgently Needed. Geneva, Switzerland: World Health Organization; 2017.
   Google Scholar
• Tato M, Morosini M, Garcia L, Alberti S, Coque MT, Canton R. Carbapenem Heteroresistance in VIM-1-producing Klebsiella pneumoniae isolates belonging to the same clone: consequences for routine susceptibility testing. J Clin Microbiol. 2010;48(11):4089–4093. doi:10.1128/JCM.01130-1020844213
   PubMed Web of Science ®Google Scholar
• Pournaras S, Kristo I, Vrioni G, et al. Characteristics of meropenem heteroresistance in Klebsiella pneumoniae carbapenemase (KPC)-producing clinical isolates of K. pneumoniae. J Clin Microbiol. 2010;48(7):2601–2604. doi:10.1128/JCM.02134-0920504985
   PubMed Web of Science ®Google Scholar
• El-Halfawy OM, Valvano MA. Antimicrobial heteroresistance: an emerging field in need of clarity. Clin Microbiol Rev. 2015;28(1):191–207. doi:10.1128/CMR.00058-1425567227
   PubMed Web of Science ®Google Scholar
• Nicoloff H, Hjort K, Levin BR, Andersson DI. The high prevalence of antibiotic heteroresistance in pathogenic bacteria is mainly caused by gene amplification. Nat Microbiol. 2019;4(3):504–514. doi:10.1038/s41564-018-0342-030742072
   PubMed Web of Science ®Google Scholar
• Ikonomidis A, Tsakris A, Kantzanou M, Spanakis N, Maniatis AN, Pournaras S. Efflux system overexpression and decreased OprD contribute to the carbapenem heterogeneity in Pseudomonas aeruginosa. FEMS Microbiol Lett. 2008;279(1):36–39. doi:10.1111/j.1574-6968.2007.00997.x18070070
   PubMed Web of Science ®Google Scholar
• Lee HY, Chen CL, Wang SB, et al. Imipenem heteroresistance induced by imipenem in multidrug-resistant Acinetobacter baumannii: mechanism and clinical implications. Int J Antimicrob Agents. 2011;37(4):302–308. doi:10.1016/j.ijantimicag.2010.12.01521353490
   PubMed Web of Science ®Google Scholar
• Netikul T, Kiratisin P. Genetic characterization of carbapenem-resistant Enterobacteriaceae and the spread of carbapenem-resistant Klebsiella pneumonia ST340 at a University Hospital in Thailand. PLoS One. 2015;10(9):e0139116. doi:10.1371/journal.pone.013911626407326
   PubMed Web of Science ®Google Scholar
• Nikaido H. Proteins forming large channels from bacterial and mitochondrial outer membranes: porins and phage lambda receptor protein. Methods Enzymol. 1983;97:85–100.6318036
   PubMed Web of Science ®Google Scholar
• Martinez-Martinez L, Pascual A, Conejo Mdel C, et al. Energy-dependent accumulation of norfloxacin and porin expression in clinical isolates of Klebsiella pneumoniae and relationship to extended-spectrum beta-lactamase production. Antimicrob Agents Chemother. 2002;46(12):3926–3932. doi:10.1128/AAC.46.12.3926-3932.200212435697
   PubMed Web of Science ®Google Scholar
• Yang D, Guo Y, Zhang Z. Combined porin loss and extended spectrum beta-lactamase production is associated with an increasing imipenem minimal inhibitory concentration in clinical Klebsiella pneumoniae strains. Curr Microbiol. 2009;58(4):366–370. doi:10.1007/s00284-009-9364-419219497
   PubMed Web of Science ®Google Scholar
• Landman D, Bratu S, Quale J. Contribution of OmpK36 to carbapenem susceptibility in KPC-producing Klebsiella pneumoniae. J Med Microbiol. 2009;58(Pt 10):1303–1308. doi:10.1099/jmm.0.012575-019556371
   PubMed Web of Science ®Google Scholar
• Hamzaoui Z, Ocampo-Sosa A, Fernandez Martinez M, et al. Role of association of OmpK35 and OmpK36 alteration and blaESBL and/or blaAmpC genes in conferring carbapenem resistance among non-carbapenemase-producing Klebsiella pneumoniae. Int J Antimicrob Agents. 2018;52(6):898–905. doi:10.1016/j.ijantimicag.2018.03.02029621592
   PubMed Web of Science ®Google Scholar
• Shon AS, Bajwa RP, Russo TA. Hypervirulent (hypermucoviscous) Klebsiella pneumoniae: a new and dangerous breed. Virulence. 2013;4(2):107–118. doi:10.4161/viru.2271823302790
   PubMed Web of Science ®Google Scholar
• Moore MR, Perdreau-Remington F, Chambers HF. Vancomycin treatment failure associated with heterogeneous vancomycin-intermediate Staphylococcus aureus in a patient with endocarditis and in the rabbit model of endocarditis. Antimicrob Agents Chemother. 2003;47(4):1262–1266. doi:10.1128/AAC.47.4.1262-1266.200312654656
   PubMed Web of Science ®Google Scholar
• Zhang F, Ding M, Yan X, et al. Carbapenem-resistant K. pneumoniae exhibiting clinically undetected amikacin and meropenem heteroresistance leads to treatment failure in a murine model of infection. Microb Pathog. 2021;160:105162. doi:10.1016/j.micpath.2021.10516234461245
   PubMed Web of Science ®Google Scholar